DRUG SAFETY NOTICE

DRUG NAME/STRENGTH/FORM:

Co-amoxiclav 125mg/31mg/5mL oral suspension Co-amoxiclav 250mg/62mg/5mL oral suspension

ISSUE

We are presently unable to acquire co-amoxiclav 125mg/31mg/5mL or 250mg/62mg/5mL oral suspensions. Supplies remaining within the Trust are limited. There is no date for resolution.

ADVICE / ALTERNATIVE

- Use co-amoxiclav in line with Trust guidelines and Microbiology advice.
- Patients able to take a tablet should be encouraged to do so (where a whole tablet dose is clinically appropriate).
- Consider alternative antibiotics where possible and clinically appropriate.
- Where required, prescribe co-amoxiclay oral suspension.
 - We have a small supply of 125/31 and 250/62 liquids remaining.
 - We have a small supply of 400/57 liquid.
 - This is not interchangeable with other liquids (dosed BD typically).
 - Switching to this formulation will require prescription amendment.
- Refer to the BNF and BNFC for full prescribing information.

ACTIONS

- Refer to Microguide and seek advice from Microbiology as required
- Be judicious with co-amoxiclav liquids to preserve stock for patients who require it.
- Ward stocks will not be affected at this time. However, use will be monitored. Inappropriate use will
 result in ward stock being withdrawn and further supplies only being made available on a named
 patient basis.

FOR FURTHER INFORMATION CONTACT YOUR WARD PHARMACY TEAM OR THE PHARMACY DEPARTMENT (City ext. 5263; Sandwell ext. 3783)

DATE OF ISSUE: 19/07/2023 **REFERENCE NUMBER:** 07-0723

